Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) with Ring Sideroblasts (RS)

被引：0
|
作者：
Komrokji, Rami S. [1 ]
Sekeres, Mikkael A. [2 ]
Zeidan, Amer M. [3 ,4 ]
Fenaux, Pierre [5 ]
Platzbecker, Uwe [6 ]
DeZern, Amy E. [7 ]
Greenberg, Peter L. [8 ]
Savona, Michael R. [9 ]
Jurcic, Joseph G. [10 ]
Verma, Amit [11 ]
Mufti, Ghulam J. [12 ]
Buckstein, Rena [13 ]
Santini, Valeria [14 ]
Laadem, Abderrahmane [15 ]
Ito, Rodrigo [15 ]
Zhang, Jennie [15 ]
Louis, Chrystal U. [15 ]
Linde, Peter G. [16 ]
Garcia-Manero, Guillermo [17 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH USA
[3] Yale Univ, Yale Sch Med, Dept Internal Med, New Haven, CT USA
[4] Yale Univ, Yale Canc Ctr, New Haven, CT USA
[5] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France
[6] Univ Hosp Leipzig, Med Clin & Policlin 1, Hematol & Cellular Therapy, Leipzig, Germany
[7] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[8] Stanford Univ, Canc Ctr, Stanford, CA 94305 USA
[9] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA
[10] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, Div Hematol Oncol, New York, NY USA
[11] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Oncol, New York, NY USA
[12] Kings Coll London, Dept Haematooncol, London, England
[13] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada
[14] Univ Florence, Azienda Osped Univ Careggi, MDS Unit, Florence, Italy
[15] Bristol Myers Squibb, Princeton, NJ USA
[16] Acceleron Pharma, Cambridge, MA USA
[17] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
MDS; myelodysplastic syndromes; clinical trial; phase III;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-280
引用
收藏
页码：S322 / S322
页数：1
相关论文
共 50 条
  • [1] Longer-term RBC transfusion reduction in the phase 3 MEDALIST study of luspatercept in patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS)
    Platzbecker, U.
    Giagounidis, A.
    Heuser, M.
    Goetze, K.
    Thol, F.
    Fenaux, P.
    Komrokji, R. S.
    Laadem, A.
    Ito, R.
    Rampersad, A.
    Zhang, J.
    Louis, C. U.
    Germing, U.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 169 - 169
  • [2] Longer-Term RBC Transfusion Reduction in the Phase III MEDALIST Study of Luspatercept in Patients With Lower-Risk MDS With Ring Sideroblasts
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 14 - 14
  • [3] Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).
    Komrokji, Rami S.
    Sekeres, Mikkael A.
    Zeidan, Amer Methqal
    Fenaux, Pierre
    List, Alan F.
    Dezern, Amy Elizabeth
    Greenberg, Peter L.
    Savona, Michael R.
    Jurcic, Joseph G.
    Verma, Amit
    Mufti, Ghulam J.
    Buckstein, Rena
    Santini, Valeria
    Laadem, Abderrahmane
    Ito, Rodrigo
    Zhang, Jennie
    Louis, Chrystal Ursula
    Linde, Peter G.
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Effects of Luspatercept on Serum Ferritin in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial
    Fenaux, Pierre
    Santini, Valeria
    Mufti, Ghulam J.
    Diez-Campelo, Maria
    Finelli, Carlo
    Sekeres, Mikkael A.
    Quesnel, Bruno
    Beyne-Rauzy, Odile
    Garcia-Manero, Guillermo
    Komrokji, Rami S.
    Buckstein, Rena
    Voso, Maria Teresa
    Selleslag, Dominik
    DeZern, Amy E.
    Greenberg, Peter L.
    Zeidan, Amer M.
    Ades, Lionel
    Verma, Amit
    Savona, Michael R.
    Laadem, Abderrahmane
    Ito, Rodrigo
    Zhang, Jennie
    Rampersad, Anita
    Sinsimer, Daniel
    Morison, Jessica
    Louis, Chrystal
    Linde, Peter G.
    Platzbecker, Uwe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S317 - S317
  • [5] Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial
    Platzbecker, Uwe
    Fenaux, Pierre
    Mufti, Ghulam J.
    Garcia-Manero, Guillermo
    Komrokji, Rami S.
    Buckstein, Rena
    Diez-Campelo, Maria
    Finelli, Carlo
    Sekeres, Mikkael A.
    Selleslag, Dominik
    DeZern, Amy E.
    Quesnel, Bruno
    Beyne-Rauzy, Odile
    Voso, Maria Teresa
    Greenberg, Peter L.
    Zeidan, Amer M.
    Ades, Lionel
    Verma, Amit
    Savona, Michael R.
    Laadem, Abderrahmane
    Ito, Rodrigo
    Zhang, Jennie
    Rampersad, Anita
    Morison, Jessica
    Louis, Chrystal
    Linde, Peter G.
    Santini, Valeria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S318 - S318
  • [6] Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.
    Zeidan, Amer Methqal
    Garcia-Manero, Guillermo
    Dezern, Amy Elizabeth
    Fenaux, Pierre
    Greenberg, Peter L.
    Savona, Michael R.
    Jurcic, Joseph G.
    Verma, Amit
    Mufti, Ghulam J.
    Buckstein, Rena
    Santini, Valeria
    Laadem, Abderrahmane
    Zhang, Jennie
    Rampersad, Anita
    Sinsimer, Daniel
    Louis, Chrystal Ursula
    Linde, Peter G.
    List, Alan F.
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Assessment of dose-dependent response to luspatercept in patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the phase 3 MEDALIST trial
    Platzbecker, U.
    Germing, U.
    Goetze, K.
    Heuser, M.
    Thol, F.
    Fenaux, P.
    Komrokji, R. S.
    Laadem, A.
    Ito, R.
    Zhang, J.
    Rampersad, A.
    Morison, J.
    Louis, C. U.
    Giagounidis, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 171 - 171
  • [8] Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study
    Zeidan, Amer M.
    Garcia-Manero, Guillermo
    DeZern, Amy E.
    Fenaux, Pierre
    Greenberg, Peter L.
    Savona, Michael R.
    Jurcic, Joseph G.
    Verma, Amit
    Mufti, Ghulam J.
    Buckstein, Rena
    Santini, Valeria
    Laadem, Abderrahmane
    Zhang, Jennie
    Rampersad, Anita
    Sinsimer, Daniel
    Louis, Chrystal U.
    Linde, Peter G.
    Platzbecker, Uwe
    Sekeres, Mikkael A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S318 - S319
  • [9] Luspatercept in patients with low-risk myelodysplastic syndromes (LR-MDS) with ring sideroblasts (RS): long-term efficacy and safety data from the phase 3 MEDALIST study
    Platzbecker, U.
    Santini, V
    Komrokji, R. S.
    Zeidan, A.
    Garcia-Manero, G.
    Buckstein, R.
    Miteva, D.
    Keeperman, K.
    Holot, N.
    Zhang, J.
    Nadal, J. A.
    Rosettani, B.
    Yucel, A.
    Fenaux, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 134 - 134
  • [10] Multiple periods of transfusion independence (TI) with luspatercept (LUSP) treatment (Tx) and the impact of dose escalation in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS) with ring sideroblasts (RS) from the MEDALIST study
    Platzbecker, U.
    Santini, V
    Komrokji, R. S.
    Zeidan, A. M.
    Garcia-Manero, G.
    Buckstein, R. J.
    Oliva, E. N.
    Pozharskaya, V
    Nadal, J. A.
    Miteva, D.
    Fenaux, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 18 - 19
12345